I think you’re conflating intervention durability with outcome durability? A child who survives cerebral malaria due to seasonal malaria chemoprevention gets to live the rest of their life; SMC programs are rerun because (mostly) new beneficiary cohorts are at highest risk, not because last year’s cohort’s survival expires somehow. Similarly with nets and child vaccinations and vitamin A deficiency prevention (i.e. the GW top charities), as well as salt iodisation and TaRL in education and many other top interventions recommended by the likes of TLYCS and FP and so on.
I’d also push back a bit on the “permanent solutions” phrasing. Infrastructure isn’t that permanent and requires ongoing expenditures and has a shelf half-life (I used to work in ops in fluid resource-constrained environments so I feel this keenly), diseases can develop resistance to vaccines so you need boosters, etc. Ex-AIM CEO Joey Savoie has a great blog talking more about how Someone Always Pays: Why Nothing Is Really “Sustainable”.
Phrasing nitpicking aside, some big funders are in fact funding more “permanent / sustainable” solutions. Open Phil Coefficient Giving’s new $120M Abundance and Growth Fund aims to “accelerate economic growth and boost scientific and technological progress while lowering the cost of living”, and Founders Pledge (which is almost OP-scale in giving) just launched a new Catalytic Impact Fund that targets “ecosystem leverage points” where small investments can build “sustainable, long-term solutions to global poverty and suffering”.
Jason’s comment above on timetable speedup is essentially how e.g. GiveWell models their grants for malaria vaccines. The model says their grant would need to speed up co-administration for all highest need children in all of subsaharan Africa by at least 9 months to clear their 10x bar, so you can interpret their grant as a bet that funding that clinical trial would in fact achieve at least 9 months speedup. Notice how it’s an uncertain bet; I think most donors (weighted by dollars moved) care quite a fair bit about certainty of direct benefits, so they’d probably donate to e.g. the Top Charities Fund instead of the more experimental EV-maxxing All Grants Fund.
I think you’re conflating intervention durability with outcome durability? A child who survives cerebral malaria due to seasonal malaria chemoprevention gets to live the rest of their life; SMC programs are rerun because (mostly) new beneficiary cohorts are at highest risk, not because last year’s cohort’s survival expires somehow. Similarly with nets and child vaccinations and vitamin A deficiency prevention (i.e. the GW top charities), as well as salt iodisation and TaRL in education and many other top interventions recommended by the likes of TLYCS and FP and so on.
I’d also push back a bit on the “permanent solutions” phrasing. Infrastructure isn’t that permanent and requires ongoing expenditures and has a shelf half-life (I used to work in ops in fluid resource-constrained environments so I feel this keenly), diseases can develop resistance to vaccines so you need boosters, etc. Ex-AIM CEO Joey Savoie has a great blog talking more about how Someone Always Pays: Why Nothing Is Really “Sustainable”.
Phrasing nitpicking aside, some big funders are in fact funding more “permanent / sustainable” solutions.
Open PhilCoefficient Giving’s new $120M Abundance and Growth Fund aims to “accelerate economic growth and boost scientific and technological progress while lowering the cost of living”, and Founders Pledge (which is almost OP-scale in giving) just launched a new Catalytic Impact Fund that targets “ecosystem leverage points” where small investments can build “sustainable, long-term solutions to global poverty and suffering”.Jason’s comment above on timetable speedup is essentially how e.g. GiveWell models their grants for malaria vaccines. The model says their grant would need to speed up co-administration for all highest need children in all of subsaharan Africa by at least 9 months to clear their 10x bar, so you can interpret their grant as a bet that funding that clinical trial would in fact achieve at least 9 months speedup. Notice how it’s an uncertain bet; I think most donors (weighted by dollars moved) care quite a fair bit about certainty of direct benefits, so they’d probably donate to e.g. the Top Charities Fund instead of the more experimental EV-maxxing All Grants Fund.